
Justin Cai
Senior Partner · Jincheng Tongda & Neal · Shanghai
Articles
- Detailed Explanation of the Core Provisions of the Cross-Border Anti-Corruption Law (Draft) and Demonstration of Simulated CasesThe Cross-Border Anti-Corruption Law (Draft) broadly defines cross-border corruption, requires enterprises to implement integrity compliance, and restricts foreign law…
- Overview of Key Compliance Points for Biosafety and Human Genetic Resources Regulation in China (2026 Edition)Pharmaceutical companies must identify and perform separate obligations for human genetic resources collection, preservation, international cooperation, export, filing…
- Review of Cross-Border BD Transactions in China's Innovative Drugs in the First Half of 2026 and Legal Observations: Expansion of Transaction Subject Matter and Evolution of Cooperation ModelsIn H1 2026, China's innovative drug cross-border BD deals expanded from single assets to multiple projects and platforms, and from one-way licensing to…
- Analysis of Patent Legal Issues in AI-Empowered Innovative Drug R&DAI drug discovery raises patent issues across R&D stages: AI cannot be an inventor, AI-assisted results must meet patentability and disclosure rules, and outsourcing…
Overview
Justin Cai started his legal practice from 2003. Before joing in JT&N in 2019, Justin has had many years’ work experience with King & Wood, Weil Gotshal, McDermott Will & Emery (China Office) and Zhong Lun Law Firm, and his practice areas mainly include cross-border M&A, life science, pharmaceutical and healthcare, dispute resolution, unfair competition investigation, financing for start-up companies, cyber-security and data-protection,.
Justin has successfully assisted foreign and Chinese clients in completing over 150 projects in these areas, with total project value amounting to USD 20 billion. In these projects, Justin has taken major responsibilities in legal/compliance due diligence, responding to government investigations, handling commercial disputes, designing deal structures and legal documentations, and has handled numerous compliance issues such as data-protection and privacy, anti-bribery, anti-fraud etc.
Justin also published many professional articles in his practices and was frequently invited as guest speaker on hot legal topics. Most of Justin’s clients are market leaders in their industries, which include 3M, Eli Lilly, Covidien, DaVita, GAP, CVRD, Invista, WWF, AVIC, Warburg, Ford Finance, Duke Kunshan University, SCB, ICBC International, China Union Pay etc.
Expertise
- Practice areas
- Life Sciences & Healthcare
- Compliance & Regulatory
- Foreign Investment
- Dispute Resolution
- Industries
- Aerospace and defence
- Life sciences and healthcare
- Manufacturing
- Real estate and construction
- Consumer and retail
- Foreign languages
- English
Representative matters
- Represented AVIC on its joint venture with GE for C919 commercial aircraft project
- Represented many well-known innovative pharmaceutical companies on the draft, review, and negotiation of technology licensing, transfer, or joint development agreements
- Represented PerkinElmer on acquisition of Shanghai SymBio and Shanghai Haoyuan
- Represented DaVita hospital on its handling of daily compliance issues in China
- Represented Covidien on its acquisition of a medical device company in Jiangsu
- Represented Galderma on product distribution compliance, advertisement investigation and problem employees
- Represented ZTO on its placing of USD 1.34 billion shares to Alibaba
- Represented Eli Lilly handlinng daily legal and compliance affairs in China
- Represented CVRD on its joint venture with China Yankuang
- Represented Invista on its establishment of a airbag manufacture plant in Shanghai
- Represented WWF on its investigation of fund donor's background
- Represented ICBC International on revoking RMB 750 million illegal share transfers made by its debtor
- Represented Huaan Fund on its reclaim of real estate debts worthing RMB 170 million
- Represented J&J on its acquisition of Dabao cosmetics
- Represented China Union Pay on its fraud site problems and monopoly accusation
- Represented many AI companies on its private equity financing
- Represented Changning Finance Buearu, Shanghai VC Center on their FOF investments
- Represented a Sino-foreign JV on its responding to FCPA investigation
- Represented a listed company on its investment in the Philliphines' real estate market
- Represented GAP on its lease of retail stores in China
Background
Professional experience
- 2019 –
JT&N
King & Wood
Weil Gotshal
McDermott Will & Emery (China Office)
China Office
Zhong Lun Law Firm
Education
- Duke University School of Law
- LL.M.
- Fudan University
- Master of Business Law
Professional appointments
- Wolters Kluwer Pharmaceutical and Healthcare Counsel Board
- MIB Project in Shanghai University of International Business and Economics
- LawReview (A WeChat platform for legal professionals)
Writing & activities
Publications
- Annual Overview of China's Life Science, Pharma and Healthcare Law and Typical Cases (from 2021 to 2025)
- Comments on the Proposed Revisions to the PRC Anti-unfair Competition Law
- China Health and Pharma Data Protection Overview
- China's Regulation on Cross-border Data Transfer
- How to Distinguish Individual Responsibilities and Corporate Responsibilities in Commercial Bribery Cases
- Legal Perspective on Establishing Enterprise Compliance System
- Negotiation Tactics in China-related Cross-border Transactions
- How to Structure Outbound Investment under Strict Government Supervision
- Going-Global Models for Innovative Pharmaceutical Companies Series (1): Key Clauses and Legal Risk Management in License-Out Agreements
- Regulation on Monopoly Agreements: Newly Revised Anti-Monopoly Law and the draft Rules on Prohibiting Monopoly Agreements
- Anti-bribery Investigations in Cross-border M&A Transactions and the Methods to Avoid Taking Successor Liabilities